• Episode #11: Professor Allan Bradley - Founder and CEO of T-Therapeutics

  • Mar 2 2025
  • Length: 43 mins
  • Podcast

Episode #11: Professor Allan Bradley - Founder and CEO of T-Therapeutics

Listen for free

View show details

  • Summary

  • Today, we’re excited to welcome Allan Bradley to Gravity Encounters. As the Founder and CEO of T-Therapeutics, Allan has had a profound impact on the fields of genomics, monoclonal antibody discovery, and biotech entrepreneurship.

    Previously, as the Director of the Wellcome Trust Sanger Institute, Allan played a pivotal role in transforming its genome-sequencing infrastructure into a world-class research centre. His academic research laid the foundation for Kymab Ltd, a humanised antibody discovery company that led to the development of novel therapeutic antibodies, some of which have demonstrated clinical benefits.

    Beyond Kymab, Allan co-founded PetMedix, applying cutting-edge antibody technologies to animal health. Earlier in his career, he spun out Lexicon Genetics while at Baylor College of Medicine, which went on to a $1 billion NASDAQ debut within just five years. A Fellow of the Royal Society and an expert in mouse genetics, Allan has significantly shaped the biotech landscape.

    Today, we’ll explore Allan’s journey, from academia to building billion-dollar companies, and the scientific and entrepreneurial insights he’s gained along the way.

    Hosts: Emily James and Jan Venne
    Show More Show Less
Show More Show Less

What listeners say about Episode #11: Professor Allan Bradley - Founder and CEO of T-Therapeutics

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.